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Abstract
Background: MicroRNAs regulate gene expression at the post-transcriptional level and involved in diverse biological and
pathological processes, including tumorigenesis. Rs11614913 in miR-196a2 and rs2910164 in miR-146a are shown to
associate with increased/decreased cancer risk. We performed a meta-analysis to systematically summarize the possible
association.
Methodology/Principal Findings: We assessed published studies of the association between these microRNA
polymorphisms and cancer risk from eleven studies with 16,771 subjects for miR-196a2 and from ten studies with 15,126
subjects for miR-146a. As for rs11614913, the contrast of homozygote (TT vs CC: OR=0.92, 95% CI=0.85–0.99,
Pheterogeneity=0.45), allele (T vs C: OR=0.96, 95% CI=0.92–0.99, Pheterogeneity=0.61) and recessive model (OR=0.90, 95%
CI=0.84–0.97, Pheterogeneity=0.50) produced statistically association. Subgroup analysis by ethnicity, statistically significantly
decreased cancer risks were found among Asians for allele contrast (OR=0.95, 95% CI=0.90–0.99, Pheterogeneity=0.74) and
the recessive genetic model (OR=0.90, 95% CI=0.82–0.98, Pheterogeneity=0.85). According to subgroup analysis by tumor
types, the protective effect of C/T polymorphism was only found in breast cancer under allele contrast (T vs C: OR=0.94,
95% CI=0.88–0.99, Pheterogeneity=0.26). For rs2910164, no significant associations were found among overall analysis model
with relatively large heterogeneity. Through the stratified analysis, heterogeneity decreased significantly. In the subgroup
analyses by cancer types, the C allele of rs2910164 was associated with protection from digestive cancer in allele contrast (C
vs G: OR=0.86, 95% CI=0.77–0.96, Pheterogeneity=0.51).
Conclusions/Significance: Our meta-analysis suggests that the rs11614913 most likely contributes to decreased
susceptibility to cancer, especially in Asians and breast cancer. Besides, the C allele of the rs2910164 might be associated
with a protection from digestive cancer.
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Introduction
MicroRNAs (miRNAs) are a class of naturally occurring, small non-
coding, single-stranded RNA molecules that form base-pairs with
target mRNAs and negatively regulate their translational efficiency and
stability [1]. Bioinformatics study indicates that a single miRNA can
bind to as many as 200 gene targets, and one-third of human genes,
including cancer-associated genes, are regulated by miRNAs [2]. A
strong link between miRNA and human cancers has been established,
as miRNAs have been demonstrated to act as either oncogenes or
tumor suppressors. The main molecular mechanism underlies changes
in the function of miRNAs in cancer cells seems to be aberrant gene
expression [3]. miRNA expression profiles have been reported to be
correlated with the etiology, classification,progression,and prognosis of
multiple human cancers. Since small variation in expression of a
specific miRNA may effect on thousands of target mRNAs and result
in diverse functional consequences [4], miRNAs represent ideal
candidates for cancer predisposition genes.
Single nucleotide polymorphisms (SNPs) or mutations occurring in
the miRNA gene region may affect the property of miRNAs through
altering miRNA expression and/or maturation [5]. However, the role
of genetic variants in miRNAs on cancer susceptibility remains largely
unknown. Recently, several reports identified genetic variants in the
precursor or mature miRNA sequence of miR-196a2 (rs11614913
[Homo sapiens],c y t o s i n et ot h y m i n e ,C RT) and miR-146a (rs2910164
[Homo sapiens], guanine to cytosine, CRG, http://www.ncbi.nlm.nih.
gov/projects/SNP) as possible biomarkers, which were associated
with multiple kind of malignant tumors, such as those that occur in the
central nervous system [6], head and neck [7], lung [8,9], esophagus
[10], stomach [11], biliary tract [12], liver [13–15], breast [16–19],
ovarian [19], prostate [20] and thyroid [21]. However, the observed
associations of these studies were inconsistent and a single study may
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polymorphism on cancer, especially when the sample size is relatively
small. Hence, we performed a meta-analysis of all eligible studies to
derive more precise estimation of the association of mir-196a2 C/T
and mir-146a G/C SNP with cancer risks.
Materials and Methods
Publication search
We carried out a search in Medline, Embase and Chinese
National Knowledge Infrastructure (CNKI) databases, covering all
papers published between 1991 and 2011, with a combination of
the following keywords: ‘‘microRNA/miR-196a2/miR-146a’’,
‘‘gene’’, ‘‘polymorphism’’ and ‘‘cancer’’ (last search was updated
on 15 Jan 2011). We evaluated potentially relevant publications by
examining their titles and abstracts and all studies matching the
eligible criteria were retrieved.
Inclusion criteria
Studies included in the current meta-analysis had to meet all the
following criteria: (a) evaluation of the rs11614913 and/or rs2910164
and cancer risks, (b) use a case-control design, (c) sufficient published
data for estimating an odds ratio (OR) with 95% confidence interval
(CI).
Data extraction
Data were independently abstracted in duplicate by two investiga-
tors (Xu and Chen) using a standard protocol and data-collection form
according to the inclusion criteria listed above. Characteristics
abstracted from the studies included the name of first author,
publication date, country origin, ethnicity, cancer type, control
characteristics, genotyping methods, total number of cases and
controls, and numbers of cases and controls with miR-196a2 C/T
and/or miR-146a G/C genotypes, respectively. Different ethnicity
descents were categorised as Caucasian and Asian.
Statistical methods
OR corresponding to 95% CI was used to assess the strength of
association between microRNA polymorphism and cancer. The
significance of the pooled OR was determined by the Z-test, and
P,0.05 was considered as statistically significant. For miR-196a2 C/T,
the meta-analysis examined the association between T allele and
cancer risk compared with that for C allele (T vs C); homozygote TT
was contrasted with CC (TT vs CC) and recessive (TT vs CC+CT) and
dominant (TT+CT vs CC) models for allele T were also used, so was
miR-146a. Subgroup analyses were done by racial descent and tumor
type.
Heterogeneity in meta-analysis refers to the variation in study
outcomes between different studies. Heterogeneity assumption was
checked by the chi-square-based Q-test [22]. A P-value.0.10 for
the Q-test indicates a lack of heterogeneity among the studies, then
the pooled OR estimate of each study was calculated by the fixed-
effects model (the Mantel-Haenszel method) [23]. Otherwise, the
random-effects model (the DerSimonian and Laird method) [24]
was used. Hardy-Weinberg equilibrium (HWE) in the control
group was assessed via Fisher’s exact test and a P-value,0.05 was
considered significant. One-way sensitivity analyses were per-
formed to determine whether the assumptions or decisions we
have made do in fact have a major effect on the results of the
review, namely, a single study in the meta-analysis was deleted
each time to reflect the influence of the individual data-set to the
pooled OR. Publication bias was assessed by visual inspection of
funnel plots in which the standard error of log (OR) of each study
was plotted against its log (OR). An asymmetric plot suggests a
possible publication bias. Funnel plot asymmetry was assessed by
the method of Egger’s linear regression test, a linear regression
approach to measure funnel plot asymmetry on the natural
logarithm scale of the OR. The significance of the intercept was
determined by the t-test (P,0.05 was considered representative of
statistically significant publication bias) [25]. All of the statistical
analyses were performed with STATA 9.2 (StataCorp, College
Station, TX), using two-sided P-values.
Results
Study characteristics
A total of 101 articles were achieved by literature search, from
the PubMed, EMBASE and CNKI database, using different
combination of key terms. As shown in Figure 1, twenty-four
eligible studies were retrieved for detailed evaluation. During the
extraction of data, eight articles [26–33] were excluded, because
they did not provide rs11614913 or rs2910164 allele frequencies
needed for OR calculation, lack of control or their contents mainly
associated with cancer prognosis and therapy, leaving 16 eligible
articles [6–21] including 21 data sets based on the search criteria.
Five studies [7,8,12,16,17] sorted the data about two kinds of
microRNAs, therefore, each group in these studies was considered
separately for pooling analyses. The characteristics of selected
studies are summarized in Table 1. A total of 11 studies [6–9,11–
14,16,17,19] involving 7,992 cases and 8,849 controls were
ultimately analyzed for rs11614913, ten studies [7,8,10,12,15–
17,19–21] involving 7,183 cases and 7,943 controls for rs2910164.
As for rs11614913, there were four studies of Caucasians
[7,12,17,19] and seven studies of Asians [6,8,9,11,13,14,16]. For
rs2910164, there were 5 groups of Asians [8,10,15,16,20] and 5 of
Caucasians [7,12,17,19,21]. The controls of all studies mainly
came from healthy population and matched for sex and age. The
distribution of genotypes in the controls did not deviate from
HWE.
Meta-analysis results
The allele frequencies were calculated for controls from the
corresponding genotype distributions. The two variant alleles had
the higher representations among controls of Asian descent (0.544
for T allele in rs11614913, 0.498 for C allele in rs2910164) than in
controls of Caucasian descent (0.375 for T allele in rs11614913,
0.246 for C allele in rs2910164) respectively.
The overall OR with its 95% CI showed statistically association
between the rs11614913 and the reduced risks of cancers (TT vs
CC: OR=0.92, 95% CI=0.85–0.99, Pheterogeneity=0.45; T vs C:
OR=0.96, 95% CI=0.92–0.99, Pheterogeneity=0.61 and the
recessive model: OR=0.90, 95% CI=0.84–0.97, Pheterogeneity=
0.50). In the subgroup analysis by ethnicity, statistically signif-
icantly decreased cancer risks were found among Asians for allele
contrast (OR=0.95, 95% CI=0.90–0.99, Pheterogeneity=
0.74, Fig. 2) and the recessive model (OR=0.90, 95%
CI=0.82–0.98, Pheterogeneity=0.85). In the tumor type subgroup
analysis, T allele had an effect of decreasing the risk of breast (T vs
C: OR=0.94, 95% CI=0.88–0.99, Pheterogeneity=0.26, Fig. 3).
For rs2910164, five kinds of genetic models did not produce
significant association among all studies with relatively large
heterogeneity (Pheterogeneity=0.03–0.41). Through stratified analy-
ses, the heterogeneity of the subgroup significantly reduced. In the
stratified analysis by racial descent, no significant risks were found
among Asians and Caucasians. Carriage of the C variant of
rs2910164 was found to be associated with protection from
digestive cancer (C vs G: OR=0.86, 95% CI=0.77–0.96,
Pheterogeneity=0.51) in the subgroup analyses by cancer types. No
rs11614913, rs2910164 and Cancer Risk
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controls) Case (%) Control (%)
CC/GG CT/GC TT/CC CC/GG CT/GC TT/CC
Hu 2008 China Asian Breast rs11614913 PCR-RFLP 1009/1093 239(24.0) 483(48.0) 287(28.0) 218(20.0) 517(47.0) 358(33.0)
rs2910164 PCR-RFLP 1009/1093 165(17.0) 515(51.0) 329(33.0) 180(17.0) 551(50.0) 362(33.0)
Xu 2008 China Asian Liver rs2910164 PCR-RFLP 479/504 80(16.7) 241(50.3) 158(33.0) 58(11.5) 249(48.4) 197(39.1)
Krystian 2008 USA Caucasian PTC rs2910164 Taqman 608/901 305(50.2) 287(47.2) 16(2.6) 526(58.4) 320(35.5) 55(6.1)
Tian 2009 China Asian Lung rs11614913 PCR-RFLP 1058/1035 253(23.9) 512(48.4) 293(27.7) 209(20.2) 519(50.1) 307(29.7)
rs2910164 PCR-RFLP 1058/1035 360(34.0) 510(48.2) 188(17.8) 364(35.2) 502(48.5) 169(16.3)
Hoffman 2009 USA Caucasian Breast rs11614913 massARRAY 441/479 181(42.5) 209(49.1) 36(8.4) 166(35.6) 229(49.1) 71(15.3)
Srivastava 2010 India Caucasian Gallbladder rs11614913 PCR-RFLP 230/230 136(59.1) 75(32.6) 19(8.3) 119(51.7) 95(41.3) 16(7.0)
rs2910164 Taqman 230/230 138(61.6) 81(36.2) 5(2.2) 129(56.1) 90(39.1) 11(4.8)
Min 2010 Korean Asian Lung rs11614913 PCR+MCS 654/640 187(28.6) 305(46.6) 162(24.8) 155(24.2) 300(46.9) 185(28.9)
Li 2010 China Asian Liver rs11614913 PCR-RFLP 310/222 78(25.2) 150(48.4) 82(26.4) 42(18.9) 102(46.0) 78(35.1)
Dou 2010 China Asian Glioma rs11614913 PCR-LDR 643/656 111(17.3) 343(53.3) 189(29.4) 143(21.8) 305(46.5) 208(31.7)
Qi 2010 China Asian Liver rs11614913 PCR-LDR 361/391 82(22.7) 179(49.6) 100(27.7) 92(23.5) 197(50.4) 102(26.1)
Catucci 2010 Italy Caucasian Breast rs11614913 PCR-RFLP 1471/1243 334(45.5) 330(43.9) 87(11.6) 532(42.8) 550(44.3) 161(13.0)
rs2910164 PCR-RFLP 754/1243 409(54.2) 286(37.9) 59(7.8) 650(52.3) 520(41.8) 73(5.9)
Germany Caucasian Breast rs11614913 PCR-RFLP 1101/1196 432(39.2) 512(46.5) 157(14.3) 584(39.0) 396(46.5) 216(14.4)
rs2910164 PCR-RFLP 813/904 459(56.0) 304(37.8) 50(6.2) 536(59.3) 318(35.2) 50(5.5)
Liu 2010 USA Caucasian SCCHN rs11614913 PCR-RFLP 1109/1130 350(31.6) 565(50.9) 194(17.5) 383(33.9) 545(48.2) 202(17.9)
rs2910164 PCR-RFLP 1109/1130 630(56.8) 411(37.1) 68(6.1) 655(58.0) 405(35.8) 70(6.2)
Peng 2010 China Asian Gastric rs11614913 PCR-RFLP 213/213 76(35.7) 94(44.1) 43(20.2) 56(26.3) 107(50.2) 50(23.5)
Xu 2010 China Asian Prostate rs2910164 PCR-RFLP 251/280 68(27.1) 135(53.8) 48(19.1) 54(19.3) 150(53.6) 76(27.1)
Guo 2010 China Asian ESCC rs2910164 SNaPshot 444/468 234(52.7) 190(42.8) 20(4.5) 206(44.0) 220(47.0) 42(9.0)
Pastrello 2010 Italy Caucasian Mix rs2910164 Sequencing 101/155 60(59.0) 36(36.0) 5(5.0) 90(58.0) 59(38.0) 6(4.0)
PTC: papillary thyroid carcinoma. ESCC: esophageal squamous cell carcinoma. SCCHN: cell carcinoma of head and neck.
doi:10.1371/journal.pone.0020471.t001
Figure 1. Flow diagram of study identification.
doi:10.1371/journal.pone.0020471.g001
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PLoS ONE | www.plosone.org 3 May 2011 | Volume 6 | Issue 5 | e20471Figure 3. Forest plot of cancer risk associated with rs11614913 under allele contrast (T vs C) in different types of cancers. The squares
and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the study specific weight (inverse of the
variance). The diamond represents the pooled OR and 95% CI.
doi:10.1371/journal.pone.0020471.g003
Figure 2. Forest plot of cancer risk associated with rs11614913 under allele contrast (T vs C) in different ethnicity. The squares and
horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the study specific weight (inverse of the variance).
The diamond represents the pooled OR and 95% CI.
doi:10.1371/journal.pone.0020471.g002
rs11614913, rs2910164 and Cancer Risk
PLoS ONE | www.plosone.org 4 May 2011 | Volume 6 | Issue 5 | e20471significant associations were found in breast cancer and other
subgroups. The data are shown in Table 2.
Bias diagnostics
Begg’s funnel plot and Egger’s test were performed to assess the
publication bias of the literature. The shapes of the funnel plot for
the comparison of the T allele and the C allele of rs11614913
seemed approximately symmetrical, and Egger’s test did not show
any evidence of publication bias (t=0.54, df=10, P=0.60, Figure
S1). So did miR-146a (t=0.56, df=9, P=0.59, Figure S2).
Sensitivity analysis
A single study involved in the meta-analysis was deleted each
time to reflect the influence of the individual data set to the pooled
ORs. The corresponding pooled ORs were not materially altered
for rs11614913. For rs2910164, one study (Catucci et al. [18]) was
considered as the main cause of heterogeneity. After exclusion of
this study, the heterogeneity no longer existed, but still reached a
negative association (Table S1).
Discussion
Much research effort has been directed toward understanding the
role of SNPs present in precursor and mature miRNA and their
influences on susceptibility and progression of various diseases.
Although hundreds of SNPs located in the regions of miRNA genes
have been identified, most of them do not affect miRNA expression
and function. However, two common SNPs, rs11614913 in miR-196a2
and rs2910164 in miR-146a, were found to alter miRNA expression
and lead to alter regulation of target mRNAs [6–21,26–33]. In the
current meta-analysis, we summarized the data on the association
between the miR-196a2 or miR-146a functional polymorphism and
cancer risks. We found a significantly protective effect of rs11614913 T
variant for cancer (Table 2), especially, in the subgroups of Asians
(Figure 2) and breast cancers (Figure 3). Besides, the C allele of the
rs2910164 might be associated with protection from digestive cancer
(Table 2).
In the subgroup analysis, our data indicated rs11614913 leaded
to reduced incidence of breast cancer. Comparing expression
levels of the mature miR-196a among miR-196a2 genotypes, Hu et
al. [27] observed significantly lower expression of miR-196a in
non-small cell lung tumor samples with CC genotype compared to
CT and TT individuals, without differential expression of pri-
miRNAs and pre-miRNAs based on genotype. In a separate
report, Hoffman et al. [17] showed increased expression of mature
miR-196a in breast cancer cells transfected with pre-miR-196a-C
vector compared with cells transfected with pre-miR-196a-T, but
did not observe differential expression of the pre-miRNA,
suggesting that miR-196a2 genotype may result in altered
processing of the pre-miR. While Christensen et al. [26] did not
detect significantly different miRNA expression by miR-196a2
genotype in either normal head and neck tissues or tumors. These
conflicting results showed a wide range of miR-196a expression
across different normal tissues, tumor types, and between tumor
and normal tissues from common sites.
Some studies have shown that the cleavage of mRNAs of HOX
gene clusters was partly miR-196a-directed [34]. Abnormal HOX
gene expression has been associated with breast cancer and
HOXD10 was recently identified as a gene target for the initiation
of breast cancer invasion and metastasis [35]. Furthermore, LSP1
Table 2. Main results of pooled ORs and stratification analysis of the miR-196a2 C/T (rs11614913) and miR-146a G/C (rs2910164)
functional polymorphisms on cancer risk in the meta-analysis.
miR-196a2 TT vs CC CT vs CC T vs C Dominant model Recessive model
C/T N OR (95% CI) Ph OR (95% CI) Ph OR (95% CI) Ph OR (95% CI) Ph OR (95% CI) Ph
Total 11 0.92(0.85–0.99)0.45 0.98(0.93–1.03)0.87 0.96(0.92–0.99)0.61 0.97(0.93–1.02)0.93 0.90(0.84–0.97)0.50
Cancer types
Breast 3 0.84(0.78–1.05)0.08 0.97(0.89–1.06)0.82 0.94(0.88–0.99)0.26 0.96(0.89–1.03)0.73 0.83(0.77–1.03)0.07
Lung 2 0.88(0.75–1.04)0.74 0.94(0.83–1.07)0.99 0.94(0.86–1.02)0.71 0.95(0.86–1.05)0.91 0.91(0.78–1.05)0.57
Liver 2 0.93(0.72–1.19)0.29 0.98(0.80–1.19)0.71 0.96(0.84–1.09)0.24 0.97(0.82–1.15)0.60 0.92(0.72–1.16)0.15
Others 4 1.01(0.87–1.18)0.69 1.02(0.92–1.04)0.29 0.99(0.92–1.07)0.53 1.00(0.93–1.02)0.48 0.95(0.83–1.10)0.87
Ethnicity
Caucasian 4 0.94(0.82–1.07)0.10 0.99(0.91–1.07)0.51 0.96(0.91–1.02)0.21 0.98(0.91–1.05)0.52 0.92(0.81–1.04)0.09
Asian 7 0.91(0.82–1.00)0.75 0.97(0.89–1.05)0.84 0.95(0.90–0.99)0.74 0.97(0.91–1.03)0.91 0.90(0.82–0.98)0.85
miR-146a CC vs GG CG vs GG C vs G Dominant model Recessive model
G/C N OR (95% CI) Ph OR (95% CI) Ph OR (95% CI) Ph OR (95% CI) Ph OR (95% CI) Ph
Total 10 0.89(0.75–1.05)0.03 1.01(0.95–1.07)0.41 0.94(0.88–1.01)0.04 0.96(0.89–1.04)0.06 0.86(0.73–1.01)0.03
Cancer types
Breast 2 1.07(0.90–1.26)0.28 0.99(0.90–1.09)0.83 0.92(0.78–1.08)0.23 0.91(0.75–1.10)0.03 0.99(0.86–1.14)0.90
Digestive 3 0.63(0.39–1.03)0.10 0.89(0.77–1.04)0.93 0.86(0.77–0.96)0.51 0.89(0.78–1.02)0.73 0.66(0.44–1.01)0.15
Others 5 0.88(0.68–1.15)0.13 1.06(0.97–1.16)0.24 1.02(0.95–1.09)0.45 1.04(0.96–1.13)0.46 0.83(0.61–1.15)0.02
Ethnicity
Caucasian 5 0.89(0.62–1.26)0.07 1.04(0.96–1.13)0.19 0.95(0.84–1.08)0.04 0.97(0.82–1.15)0.01 0.80(0.56–1.15)0.05
Asian 5 0.87(0.70–1.07)0.05 0.97(0.89–1.06)0.80 0.94(0.86–1.02)0.12 0.97(0.72–1.04)0.63 0.87(0.72–1.06)0.05
N indicates number of studies involved; Ph: P-value of Q-test for heterogeneity test.
doi:10.1371/journal.pone.0020471.t002
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5p respectively, and these genes were also identified as novel breast
cancer susceptibility markers. By other evidence in vitro, Hoffman
et al. [17] corroborated down-regulation of tumor suppressors
(HOXB2, HOXB3, HOXB13, HOXB5, GADD45G, INHBB) and up-
regulation of oncogenes (TP63, S100A8, S100A9) by introduction
of pre-miR196a-C would be consistent with overall oncogenic
activity, and the diminished regulatory activity of pre-miR196a-T
is consistent with a protective role for the T allele of the SNP in
breast cancer cells.
Rs2910164 in the miR-146a gene is located in the stem region
opposite to the mature miR-146 sequence and results in a change
from G:U pair to C:U mismatch in the stem structure of miR-146a
precursor. In two separate studies, Xu et al. [15] and Jazdzewski et
al. [21] reported that the G-allelic miR-146a precursor displayed
increased production of mature miR-146a compared with the C-
allelic one in cell model system and then the miR-146a could
obviously promote cell proliferation and colony formation.
Jazdzewski et al. [21] also found that rs2910164 in miR-146a
could affect target mRNA binding. In this meta-analysis,
significant association was found about this polymorphism with
cancer risk only in the digestive cancer subgroup, and further
evaluations were warranted to confirm these results.
One important property of the gene polymorphisms is that their
incidence can vary substantially between different racial or ethnic
populations. In this meta-analysis, we found highly significant
differences in the prevalence of the rs11614913 T allele and
rs2910164 C allele among controls of Asian (0.544, 0.498,
respectively) and Caucasian (0.375, 0.246, respectively). In the
subgroup analysis by ethnicity, the association between T variant
genotypes of rs11614913 and reduced risks of cancer was
significant only in Asians but not in Caucasians, suggesting genetic
diversity among different ethnicities.
Caution must be made about the interpretation of the results
because of the relatively large heterogeneity in rs2910164 studies.
In the subgroup analyses stratified by tumor site and racial descent
respectively, it can be found that the heterogeneity of the subgroup
reduced significantly. Therefore, it can be presumed that the
relatively large heterogeneity mainly results from differences of
ethnicity and tumor types. Simultaneously, the heterogeneity may
also have been caused by the differences in the selection of
subjects, such as familial breast cancer cases negative for disease-
causing mutation in Catucci’s research [18]. Publication bias may
exist, because only published studies were included in this meta-
analysis, although the result for publication bias was not
statistically significant. Finally, lack of the original data of the
reviewed studies limited our further evaluation of potential
interactions, because the interactions between gene-to-gene and
gene-to-environment may modulate cancer risk.
In summary, this meta-analysis supports that the rs11614913 in
miR-196a2 most likely contributes to decreased susceptibility to
cancer, especially in the subgroup of Asians and breast cancer.
Besides, the C allele of rs2910164 in miR-146a might be associated
with protection from digestive cancer. Larger well-designed studies
with subjects of the same ethnic background and tissue-specific
biochemical and biological characterization are warranted to
validate these findings.
Supporting Information
Figure S1 Funnel plot of publication bias in rs11614913
studies. Log OR is plotted versus standard error for each of
studies in this meta-analysis. Each point represents a separate
study for the indicated association by T over C allele.
(DOCX)
Figure S2 Funnel plot of publication bias in rs2910164
studies. Each point represents a separate study for the indicated
association by C over G allele.
(DOCX)
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